Joseph A Metzger

US Patent:

7845282, Dec 7, 2010

Filed:

May 30, 2007

Appl. No.:

11/806221

Inventors:

Edward W. Sheridan - Orlando FL, US
George D. Hugus - Chuluota FL, US
Joseph G. Metzger - Grapevine TX, US

Assignee:

Lockheed Martin Corporation - Bethesda MD

International Classification:

F42B 12/22

US Classification:

102473, 102491, 102492, 102497, 102476, 102475

Abstract:

A munition includes a casing, the casing formed at least in part from a material comprising (i) a meltable or phase-changing material, and (ii) an energetic material; an explosive payload contained within the casing; and a fuze arrangement, the fuze arrangement comprising a main fuze configured and arranged to ignite the high explosive, and at least one secondary fuze configured and arranged to cause the casing material to melt or undergo a phase change. A method of selectively altering the mode of operation of a munition includes: forming a casing, the casing comprising a material comprising (i) a meltable or phase-changing material, and (ii) an energetic material; introducing an explosive payload into the casing; providing a fuze arrangement comprising a main fuse and at least one secondary fuze configured and arranged to cause the casing material to melt or undergo a phase change; and selectively activating the main fuze and the at least one secondary fuze in a manner that provided at least a first and a second mode of operation, the first mode of operation comprising blast coupled with fragmentation effects, and the second mode of operation comprising mainly blast effects.

US Patent:

8033223, Oct 11, 2011

Filed:

Jun 11, 2010

Appl. No.:

12/814226

Inventors:

Edward W. Sheridan - Orlando FL, US
George D. Hugus - Chuluota FL, US
Joseph G. Metzger - Grapevine TX, US

Assignee:

Lockheed Martin Corporation - Bethesda MD

International Classification:

F42B 12/22

US Classification:

102473, 102491, 102492, 102497, 102476, 102475

Abstract:

A munition includes a casing, the casing formed at least in part from a material comprising (i) a meltable or phase-changing material, and (ii) an energetic material; an explosive payload contained within the casing; and a fuze arrangement, the fuze arrangement comprising a main fuze configured and arranged to ignite the high explosive, and at least one secondary fuze configured and arranged to cause the casing material to melt or undergo a phase change. A method of selectively altering the mode of operation of a munition includes: forming a casing, the casing comprising a material comprising (i) a meltable or phase-changing material, and (ii) an energetic material; introducing an explosive payload into the casing; providing a fuze arrangement comprising a main fuse and at least one secondary fuze configured and arranged to cause the casing material to melt or undergo a phase change; and selectively activating the main fuze and the at least one secondary fuze in a manner that provided at least a first and a second mode of operation, the first mode of operation comprising blast coupled with fragmentation effects, and the second mode of operation comprising mainly blast effects.

US Patent:

20120165503, Jun 28, 2012

Filed:

Dec 18, 2009

Appl. No.:

13/202524

Inventors:

Paul E. Carrington - Rahway NJ, US
George Eiermann - Rahway NJ, US
Donald Marsh - Rahway NJ, US
Joseph Metzger - Rahway NJ, US
Alessandro Pocai - Rahway NJ, US
Ranabir Sinha Roy - Rahway NJ, US
Bianchi Bianchi - Pomezia, IT
Paolo Ingallinella - Pomezia, IT
Antonello Pessi - Pomezia, IT
Alessia Santoprete - Pomezia, IT
Elena Capito - Pomezia, IT
Richard Dimarchi - Indianapolis IN, US
Brian Ward - Bloomington IN, US

International Classification:

C07K 14/605

US Classification:

530308

Abstract:

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.

US Patent:

20150307580, Oct 29, 2015

Filed:

Apr 14, 2015

Appl. No.:

14/686760

Inventors:

- Rahway NJ, US
- Roma, IT
- Indianapolis IN, US
Joseph M. METZGER - Rahway NJ, US
Alessandro POCAI - Rahway NJ, US
Ranabir SINHA ROY - Rahway NJ, US
Elisabetta BIANCHI - Pommezia, IT
Paolo INGALLINELLA - Pommezia, IT
Antonello PESSI - Pommezia, IT
Alessia PRETE - Pommezia, IT
Elena CAPITO - Pommezia, IT
Richard DIMARCHI - Indianapolis IN, US
Brian WARD - Bloomington IN, US

International Classification:

C07K 14/605

Abstract:

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.